However, the 2012 phase 3 ALFA-0701 trial demonstrated that fractionated lower doses (3 mg/m2) improved outcomes in AML patients with manageable toxicity, leading to its reapproval by the FDA in 2017 for CD33-positive AML treatment in adults and children (Pawinska-Wasikowska et al., 2023). The gene discussed is CD33; the disease is acute myeloid leukemia.